Brilliant Blue G Ophthalmic Solution

(TissueBlue®)

Brilliant Blue G Ophthalmic Solution

Drug updated on 9/5/2024

Dosage FormInjection (intraocular: 0.025%)
Drug ClassDisclosing agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to selectively stain the internal limiting membrane (ILM).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Tissueblue (brilliant blue g ophthalmic solution) is indicated to selectively stain the internal limiting membrane (ILM).
  • This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
  • IMH Closure Rate: BBG-assisted ILM peeling consistently achieved the highest postoperative macular hole (IMH) closure rates across studies, outperforming other dyes such as ICG, TA, and TB.
  • Visual Acuity Improvement: BBG and the inverted ILM flap technique led to the most significant improvements in postoperative visual acuity (logMAR BCVA), with BBG showing superior outcomes compared to ICG and other adjuvants.
  • Comparison with Other Drugs: BBG demonstrated greater effectiveness in both IMH closure rates and visual acuity improvement compared to ICG, TA, TB, and the absence of dye across studies.
  • There is no safety information available in the reviewed studies.
  • There is no population types or subgroups information available in the reviewed studies.